A woman with glasses looking to the side

How QINLOCK can help to treat advanced GIST

Learn how QINLOCK was studied in a clinical trial

QINLOCK was studied in a clinical trial of 129 people with advanced GIST who were treated with at least 3 prior lines of therapy. People in the study were randomly assigned to receive either QINLOCK or placebo (a pill with no active medication). The trial had 2 main goals: to study how well QINLOCK works and how safe it is.

Progression-free survival:

Patients who took QINLOCK lived significantly longer without their cancer growing or spreading compared to placebo

Progression-free survival (PFS) is how long a person lives without their tumor growing or spreading. Among all the patients who took QINLOCK, the median PFS was 6.3 months, compared with 1.0 month for patients on placebo.*

*Median means the middle number in a group arranged from lowest to highest. This means half the people had results that were better and half the people had results that were worse.

Median progression-free survival on QINLOCK

6.3 months

Median progression-free survival on placebo

1.0 month

QINLOCK reduced the risk of disease progression or death by 85% compared to placebo

Objective response rate:

Some people who took QINLOCK saw their tumors shrink

9% of people who took QINLOCK saw their tumors shrink versus none (0%) on placebo^†

^†This result was not statistically significant.

Overall survival:

QINLOCK may have helped people live longer

An image of a calendar page with 15.1 months written on it

With QINLOCK, the median overall survival was 15.1 months compared to 6.6 months with placebo^‡§

^‡Because of the order in which the data were analyzed, it was not possible to draw conclusions about these results.

^§Median overall survival is the length of time after starting the study in which half of the patients in the group are expected to still be alive.